Today it was reported that the CEO & Chairman of Pacira Pharmaceuticals (PCRX), David Stack, exercised options to buy 24,000 PCRX shares at $3.06 a share, for a total transaction value of $73.56K.
Following this transaction David Stack’s holding in the company was increased by 15.38% to a total of $8.33 million. In addition to David Stack, 4 other PCRX executives reported Buy trades in the last month.
See today’s analyst top recommended stocks >>
Based on Pacira Pharmaceuticals’ latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $91.31 million and GAAP net loss of $2.77 million. In comparison, last year the company earned revenue of $74.61 million and had a GAAP net loss of $10.68 million. PCRX’s market cap is $1.79B and the company has a P/E ratio of 252.03. Currently, Pacira Pharmaceuticals has an average volume of 441.7K.
Based on 9 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $54.56, reflecting a 23.8% upside. Five different firms, including Barclays and Piper Jaffray, currently also have a Buy rating on the stock.
In the last 30 days, insiders have sold $339.1K worth of PCRX shares and purchased $73.56K worth of PCRX shares. The insider sentiment on Pacira Pharmaceuticals has been negative according to 58 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
David Stack’s trades have generated a 1.6% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Pacira Biosciences, Inc. operates as a holding company, which engages in the development, commercialization, and manufacture of pharmaceutical products for use in postsurgical outcomes for acute care practitioners and their patients.
